Other substances

Iloprost

A prostacyclin analogue.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Iloprost on PubChem

Marketed as

VENTAVIS

CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/C2)O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Superiority of cilostazol among antiplatelet FDA‐approved drugs against COVID 19 Mpro and spike protein: Drug repurposing approach Spike protein 3CLpro Small molecule In silico Screening	in silico	1.90	Predicted to inhibit the SARS-CoV-2 spike protein.	Sep/27/2020

AI-suggested references

Link	Publication date
Compassionate use of Pulmonary Vasodilators in Acute Severe Hypoxic Respiratory Failure due to COVID-19.	Oct/29/2020
Investigacion cientifica prioritaria en Latinoamerica para orientar la prevencion y el control de la COVID-19	Sep/16/2021
Upregulation of cAMP prevents antibody-mediated thrombus formation in COVID-19	Oct/11/2021
Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 Mpro and spike protein: Drug repurposing approach	Jan/22/2021

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04420741	Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure	Completed	Phase 2	Jun/15/2020	Apr/23/2021
Alternative id - COMBAT-COVID-19\|2020-001296-33 Interventions - Drug: Iloprost\|Drug: Isotonic saline Study type - Interventional Study results - No Results Available Locations - Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital, Copenhagen, Denmark\|Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark\|Dept. of Intensive Care, Copenhagen University Hospital Herlev, Herlev, Denmark\|Dept. of Anaesthesia and Intensive Care, Nordsjaelands Hospital, Hillerød, Denmark\|Dept. of Anaesthesia and Intensive Care, Hvidovre Hospital, Hvidovre, Denmark Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 80 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Mechanical ventilation free days\|28 and 90-day mortality\|Modified Sequential Organ Failure Assessment (SOFA)\|Vasopressor free days\|Renal replacement free days\|Serious adverse reactions (SARs)\|Serious adverse events (SAEs)
NCT04445246	Inhaled Iloprost for Suspected COVID-19 Respiratory Failure	Recruiting	Phase 2	May/23/2020	May/31/2021
Alternative id - MRC-05-026 Interventions - Drug: Inhaled ILOPROST Study type - Interventional Study results - No Results Available Locations - Hamad Medical Corporation, Doha, Qatar Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 40 Age - 18 Years and older (Adult, Older Adult) Outcome measures - change in oxygenation parameters\|Rates of endotracheal intubation\|Invasive ventilation duration\|ICU length of stay\|Hospital Length of stay\|Rates of proning therapy\|Rates of ECMO cannulation\|Mortality

Export (.csv)